USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Qilu Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 8 granted patents across 10 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Qilu ranks #32,975 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 10 technology areas.

#32,975
of 49,997 US assignees by volume
26th percentile
by Innovation Score (28.0/100)
15.4
avg claims per patent
+0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32975 · Foreign Corporation #32,975 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

  • GRANTS-MICRO 8 grants
  • MID-PACK #32,975/49,997
  • PHOTO-FINISH Puricore
  • CPC-FOCUS A61P · 10 areas
  • INNOV-THIN 28.0/100
  • CLAIMS-RICH 15.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-FLAT +0% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Puricore, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Qilu

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Qilu's Innovation Score is 28.0/100 (26th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Qilu's grants concentrate

Qilu Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 10 CPC subclasses with 87.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2019. By volume, Qilu sits between Puricore, Inc. and Qlight Nanotech Ltd..

Who files at Qilu's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Qilu holds 8 patents at rank #32,960, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Qilu

By rank, the assignees closest to #32,960 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Qilu's primary technology class.

Qilu's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 26th percentile higher than 26% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 20182019202020212025 2
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Qilu Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 2 25.0%
2019 1 12.5%
2020 2 25.0%
2021 1 12.5%
2025partial year 2 25.0%

Where it ranks

Overall rank by patents

#32,975

of 49,997 tracked assignees

Innovation Score

28.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Qilu Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

  • Qilu Pharmaceutical Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.5% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #32,975 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Qilu Pharmaceutical Co., Ltd. against Puricore, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 28.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.